NAD+ before & after.

NAD+ before and after: the measured changes

Direct NAD+ can produce a measurable blood-level change within hours. In a small supervised study, plasma NAD+ was 398% above its starting level at the end of a six-hour infusion. The trial did not measure a matching increase in energy, memory or exercise performance. [1]

Eight men received 750 mg NAD+ over six hours; three received saline. These are plasma measurements from a pilot infusion study, not a percentage improvement in how someone feels. The multiple is calculated as 1 + 3.98. [1]

For someone interested in better energy or clearer thinking, that is a useful first finding: the intervention changed something measurable. It does not yet establish the size of the everyday benefit. There is no verified “before” photograph, pounds-lost figure or reduction in biological age for the supplied vial, pen or nasal spray.

What happened during the first eight hours?

The blood response did not simply rise in step with every milligram infused. NAD+ was being handled by the body throughout the session. The investigators observed no significant plasma rise at the measured time points through two hours, followed by the large change at six hours; levels remained elevated two hours after the infusion ended. [1]

A circulating molecule can be taken up, broken down, recycled or excreted. A blood test is a snapshot of the amount present in that sample after those processes have occurred. It does not show that every tissue received the same increase or that all the administered material remained available in its original form.

The study therefore cannot answer how many days one administration “lasts.” A higher final value does not provide an established maintenance interval, and a delayed rise during an infusion does not mean a person should increase its rate or use more product.

Energy and fatigue: what could you actually notice?

A dependable time to improved energy has not been established for direct NAD+ injections or the supplied spray. Available studies do not provide a validated answer such as a certain number of doses before fatigue improves, or a predictable number of productive hours gained.

That uncertainty also prevents a firm “loading phase” claim for wellness use. Completing several administrations does not itself demonstrate that a physiological store has been filled or that a lasting energy improvement should follow. The relevant test would compare a defined symptom or functional outcome against an appropriate control.

A person may report feeling better after an appointment. That experience can be real while its cause remains uncertain: rest, expectations, hydration or other simultaneous changes can accompany the intervention. Without a suitable comparison, an individual account cannot establish how often the same result will occur or which part of a mixed treatment produced it.

Feeling unwell during administration should not be presented as the necessary first stage of a good result. The side-effects article separates reported treatment symptoms from the outcomes someone is trying to achieve.

After a short injection course

A 2026 preliminary safety report included small direct NAD+ groups receiving 100 mg injections once daily for three days. Across its nine groups, the first trial enrolled 45 participants; direct NAD+ was given subcutaneously to six, intramuscularly to four and intravenously to five. The other groups received NR or placebo. [2]

The report supported further investigation of short supervised administration. It did not establish an energy, strength, sleep or cosmetic transformation, and its small groups cannot define an ongoing home-use response rate. The publication is a preprint, so its findings had not undergone peer review when published.

Its direct-NAD+ results also should not be merged with the second trial merely because both appear in the same report. That separate investigation used the precursor NR. Compound names matter here: changing the substance changes what can be concluded about a product.

The dosage article gives the study setting and amount calculations separately. A research regimen is evidence of what investigators tested; it is not a prediction of what the supplied 1,000 mg vial will do for someone over a chosen number of weeks.

Thirty-day results: blood markers and body composition

A small clinic-record study followed six NAD+ recipients for 30 days after four consecutive days of 500 mg IV infusions. It also included eight people who received IV NR. The retrospective design and small groups make these exploratory observations. [3]

This was a review of commercial-clinic records, not a large placebo-controlled wellness trial. A lower HDL result is not an established benefit of NAD+ treatment. [3]

“No significant change” does not mean every person had exactly the same result before and after. It means the study did not establish a reliable change in that outcome. Small groups can miss modest effects, but that possibility cannot be turned into a promised positive result.

The measurements also show why a general claim such as “improves all metabolic markers” is too broad. Different markers moved differently, some did not change convincingly, and a result from the NR recipients cannot be reassigned to the NAD+ recipients.

Weight loss, muscle gain and visible changes

There is no defensible average in pounds, kilograms or body-fat percentage for a course of the supplied NAD+ products. The 30-day body-composition finding above provides no basis for a promised physical transformation. There is also no validated before-and-after series showing that this vial, pen or spray builds a particular amount of muscle. [3]

A change on the scale can have several components, including water and lean tissue as well as fat. A comparison intended to establish fat loss needs to measure that outcome specifically. Simply showing a smaller number after a course does not identify what changed or whether NAD+ caused it.

Skin photographs have similar limits. Lighting, camera distance, facial expression and other treatments can change the apparent result. Without a controlled assessment, photographs cannot establish collagen production, a reduction in wrinkle depth or a reversal of aging.

For a purchase decision, compare total amount, concentration, preparation needs and batch testing alongside the measured clinical outcomes.

Mental clarity, sleep and recovery over weeks

Some newer injection headlines concern NR rather than NAD+. October 2026 preprints described NR injections over three days and an approximately 90-day home phase. They included exploratory reports about fatigue, sleep and other symptoms. The long home phase did not test direct NAD+ in the supplied pen or vial. [4]

These results can guide further research, but a schedule of “three times a week for three months” from an NR study cannot become an NAD+ benefits protocol. Similar names and a shared biochemical pathway do not make the products interchangeable.

For exercise recovery, an oral NR trial in older men changed muscle NAD-related metabolites without improving the measured mitochondrial energy-production function. Again, the distinction is useful: a laboratory sign of exposure and a meaningful functional result are separate findings. [5]

Direct NAD+ has not supplied a dependable timeline for sharper memory, more restorative sleep or faster recovery from a workout. The benefits article explains the biological reasons these outcomes are being studied, without converting them into an expected personal response.

Actual before-and-after findings in heart patients

A randomized hospital trial found a greater improvement in heart-pumping function when IV NAD+ was added to standard care. The participants had heart failure caused by ischemic cardiomyopathy. They received 10 mg daily for seven days, with assessment at one month. [6]

LVEF is the percentage of blood pumped out of the left ventricle per beat. Both groups received heart treatment; the trial enrolled 180 participants. Six-month clinical events did not differ significantly. These results concern hospital therapy, not consumer energy or athletic performance. [6]

A separate 120-patient trial after a treated heart attack reported 30-day LVEF values of 56.32% with NAD+ and 53.37% with placebo, alongside standard care. That is a 2.95-percentage-point difference between the final group averages. It did not establish a significant difference in major clinical events at six months. [7]

These positive functional findings justify further disease-specific research. They cannot establish that an otherwise healthy person will feel more energetic or that a different amount, route or formulation reproduces the hospital result.

How long do results last after stopping?

A lasting wellness benefit after stopping direct NAD+ has not been quantified. An observation window tells us when researchers collected data. It does not automatically identify how long an effect lasts, the best interval between administrations or a need for maintenance treatment.

The different study windows also answer different questions. A session-length blood study describes short-term handling. A 30-day assessment can examine later laboratory or body-composition outcomes. A hospital trial can follow disease-related events for months. None of these schedules supplies a universal timetable for energy or focus from a research pen.

Claims that a particular course “resets” NAD+ for a fixed number of weeks require evidence that the relevant result stays improved after treatment ends. The current direct-product findings do not supply that duration, so it should not be used to calculate an automatic repeat-purchase interval.

What changes when choosing a vial, pen or spray?

The 1,000 mg vial contains dry powder; the prefilled pen contains 1,500 mg in 3 mL at 500 mg/mL. The vial requires preparation, while the pen is already a liquid. The nasal spray uses a different delivery route, so an IV blood result does not establish its absorption or clinical effect. [8]

The nasal bottle contains 30 mg in 200 sprays, equal to 150 mcg (0.15 mg) per spray. Two sprays contain 300 mcg; four contain 600 mcg. These figures describe the amount dispensed by the product. [8]

Compare preparation, storage and batch testing in the product comparison. For spray amounts, concentration examples and the interactive vial calculator, use the dosage page.